Substantial increases in revenue and profit driven by strong sales of new drugs
First written in FY2016. . Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026Full-year results updated; revenue up, profit down (core operating profit declined)Annual report
「Revenue for the consolidated fiscal year was ¥610,497 million (compared with ¥600,370 million in the previous fiscal year). Operating income was ¥4,027 million (¥5,706 million), ordinary income was ¥7,822 million (¥6,970 million), and profit attributable to owners of the parent was ¥7,362 million (¥7,308 million).」
FY2026 full-year revenue increased and operating income declined, while ordinary income and profit attributable to owners of the parent increased. - FY2026-H1Interim results updated; higher revenue and lower profitAnnual report
「For the interim consolidated accounting period, revenue was ¥300,234 million (101.1% of the prior-year period), and operating income was ¥1,641 million (57.1%). Core operating income before deducting research and development expenses in the pharmaceutical business, a new business supporting the introduction of unapproved drugs, was ¥2,233 million (77.7% of prior-year operating income).」
The consolidated interim results for FY2026 have been updated. Revenue increased, while operating income declined. Core operating income before deducting research and development expenses in the pharmaceutical business has also been disclosed for the first time. - FY2025Full-year results updated; higher revenue and profitAnnual report
「Revenue for the consolidated fiscal year was ¥600,370 million (compared with ¥587,481 million in the previous fiscal year). Operating income was ¥5,706 million (¥5,556 million), ordinary income was ¥6,970 million (¥6,557 million), and profit attributable to owners of the parent was ¥7,308 million (¥5,843 million).」
The consolidated results for FY2025 have been updated. Revenue, operating income, ordinary income, and profit attributable to owners of the parent all exceeded the previous fiscal year. - FY2025-H1Interim results updated; higher revenue and profitAnnual report
「For the interim consolidated accounting period, consolidated results were revenue of ¥297,079 million (101.0% of the previous interim consolidated accounting period), operating income of ¥2,876 million (100.3%), ordinary income of ¥3,637 million (104.6%), and interim profit attributable to owners of the parent of ¥2,420 million (103.1%).」
The consolidated results for the interim consolidated accounting period of FY2025 have been updated. Revenue, operating income, ordinary income, and interim profit attributable to owners of the parent all exceeded the prior-year period. - FY2024Full-year results updated; higher revenue and profitAnnual report
「Revenue for the consolidated fiscal year was ¥587,481 million (compared with ¥581,327 million in the previous fiscal year). Operating income was ¥5,556 million (¥4,024 million), ordinary income was ¥6,557 million (¥5,960 million), and profit attributable to owners of the parent was ¥5,843 million (¥4,831 million).」
The consolidated results for FY2024 have been updated, and revenue, operating income, ordinary income, and profit attributable to owners of the parent all exceeded the previous fiscal year. - FY2024-Q3Third-quarter results updated; higher revenue and profitAnnual report
「As a result, revenue was ¥448,909 million (compared with ¥444,384 million in the prior-year period), operating income was ¥5,658 million (¥3,061 million), ordinary income was ¥6,506 million (¥4,302 million), and quarterly profit attributable to owners of the parent was ¥5,054 million (¥2,433 million).」
The consolidated results for the cumulative third-quarter period of FY2024 have been updated. Revenue increased slightly, while operating income, ordinary income, and quarterly profit attributable to owners of the parent exceeded the prior-year period. - FY2024-Q2Second-quarter results updated; higher revenue and profitAnnual report
「For the six months ended 30 September, consolidated results were revenue of ¥294,213 million (compared with ¥290,166 million in the prior-year period), operating income of ¥2,868 million (¥1,521 million), ordinary income of ¥3,478 million (¥2,423 million), and quarterly profit attributable to owners of the parent of ¥2,347 million (¥1,437 million).」
The consolidated results for the cumulative second-quarter period of FY2024 have been updated. Revenue, operating income, ordinary income, and quarterly profit attributable to owners of the parent all exceeded the prior-year period. - FY2024-Q1First-quarter results updated; higher revenue and profitAnnual report
「For the cumulative period, consolidated results were revenue of ¥144,542 million (compared with ¥143,919 million in the prior-year period), operating income of ¥1,167 million (¥849 million), ordinary income of ¥1,470 million (¥1,198 million), and quarterly profit attributable to owners of the parent of ¥917 million (¥640 million).」
The consolidated results for the first quarter of FY2024 have been updated. Revenue, operating income, ordinary income, and quarterly profit attributable to owners of the parent all exceeded the prior-year period. - FY2023Full-year results updated; lower operating profitAnnual report
「Revenue for the consolidated fiscal year was ¥579,772 million, up 0.4% from the previous consolidated fiscal year. Operating income was ¥2,470 million, down 16.1%, ordinary income was ¥5,960 million, up 2.2%, and profit attributable to owners of the parent was ¥4,831 million, up 1.3%.」
FY2023 full-year results have been updated. Revenue, ordinary income, and net income increased, while operating income declined 16.1%. - FY2023-Q3Third-quarter results updated; higher revenue and lower profitAnnual report
「For the nine months ended 31 December, consolidated results were revenue of ¥443,190 million (100.9% of the prior-year period), operating income of ¥1,866 million (89.5%), ordinary income of ¥4,302 million (101.9%), and quarterly profit attributable to owners of the parent of ¥2,433 million (99.4%).」
The consolidated results for the cumulative third-quarter period of FY2023 have been updated. Revenue and ordinary income exceeded the prior-year period, while operating income and quarterly profit attributable to owners of the parent were below the prior-year period. - FY2023-Q2Interim results updated; higher revenue and lower profitAnnual report
「For the six months ended 30 September, consolidated results were revenue of ¥289,376 million (101.5% of the prior-year period), operating income of ¥730 million (78.2%), ordinary income of ¥2,423 million (102.8%), and quarterly profit attributable to owners of the parent of ¥1,437 million (101.9%).」
The consolidated results for the cumulative second-quarter period of FY2023 have been updated. Revenue, ordinary income, and quarterly profit attributable to owners of the parent exceeded the prior-year period, while operating income declined. - FY2023-Q1First-quarter results updated; higher revenue and profitAnnual report
「For the cumulative period, consolidated results were revenue of ¥143,521 million (100.4% of the prior-year period), operating income of ¥452 million (119.8%), ordinary income of ¥1,198 million (112.3%), and quarterly profit attributable to owners of the parent of ¥640 million (99.4%).」
In the first quarter of FY2023, revenue, operating income, and ordinary income exceeded the prior-year period, while quarterly profit attributable to owners of the parent was slightly below the prior-year period. - FY2022Full-year results updated; return to profitabilityAnnual report
「Revenue for the consolidated fiscal year was ¥577,249 million, up 7.5% from the previous consolidated fiscal year. Operating income turned around from an operating loss of ¥2,260 million in the previous consolidated fiscal year to profit of ¥2,945 million in the current fiscal year.」
FY2022 full-year revenue increased, and operating income turned from a loss of ¥2,260 million in the previous fiscal year to profit of ¥2,945 million. - FY2022-Q3Third-quarter results updated; higher revenue and profitAnnual report
「For the cumulative third-quarter period, consolidated results were revenue of ¥439,329 million (107.5% of the prior-year period), operating income of ¥2,086 million (compared with an operating loss of ¥1,682 million in the prior-year period), ordinary income of ¥4,220 million (765.7% of the prior-year period), and quarterly profit attributable to owners of the parent of ¥2,448 million (729.2% of the prior-year period).」
In the cumulative third-quarter period of FY2022, revenue was 107.5% of the prior-year period, and operating income turned from an operating loss in the prior-year period to profit of ¥2,086 million. - FY2022-Q2Second-quarter results; return to profitabilityAnnual report
「For the cumulative period, consolidated results were revenue of ¥285,229 million (107.0% of the prior-year period), operating income of ¥934 million (compared with an operating loss of ¥1,111 million in the prior-year period), ordinary income of ¥2,355 million (539.2% of the prior-year period), and quarterly profit attributable to owners of the parent of ¥1,411 million (321.6% of the prior-year period).」
The cumulative second-quarter period of FY2022 saw higher revenue, and operating income turned from an operating loss in the prior-year period to profit of ¥934 million. Ordinary income and quarterly profit attributable to owners of the parent also increased. - FY2022-Q1First-quarter results updated; returned to profitabilityAnnual report
「For the cumulative period, consolidated results were revenue of ¥142,916 million (105.8% of the prior-year period), operating income of ¥377 million (compared with an operating loss of ¥932 million in the prior-year period), ordinary income of ¥1,067 million (compared with an ordinary loss of ¥225 million), and profit attributable to owners of the parent of ¥644 million (compared with a quarterly net loss attributable to owners of the parent of ¥257 million).」
FY2022 first-quarter results have been updated. Revenue increased 5.8% year on year, and operating income, ordinary income, and quarterly profit attributable to owners of the parent all turned from losses in the prior-year period to profits. - FY2021Full-year results updated; operating lossAnnual report
「Revenue for the consolidated fiscal year was ¥537,030 million, down 4.5% from the previous consolidated fiscal year. The Company recorded an operating loss of ¥2,260 million, a 163.6% decrease from the previous year. Ordinary income was ¥693 million, down 89.2%, and profit attributable to owners of the parent was ¥1,171 million, down 74.8%.」
FY2021 full-year results have been added. Revenue declined 4.5%, and operating income turned into a loss of ¥2,260 million. - FY2021-Q3Third-quarter results updated; lower revenue and operating lossAnnual report
「For the cumulative third-quarter period, consolidated results were revenue of ¥408,829 million (94.5% of the prior-year period), an operating loss of ¥1,682 million (compared with operating income of ¥3,090 million in the prior-year period), ordinary income of ¥551 million (10.2% of the prior-year period), and profit attributable to owners of the parent of ¥335 million (7.2% of the prior-year period).」
The consolidated results for the cumulative third-quarter period of FY2021 have been updated. Revenue declined, and operating income turned from a profit in the prior-year period to an operating loss of ¥1,682 million. - FY2021-Q2First-half results updated; revenue down and operating loss recordedAnnual report
「For the six months ended 30 September, consolidated results were revenue of ¥266,670 million (93.4% of the prior-year period), an operating loss of ¥1,111 million (compared with operating income of ¥1,436 million in the prior-year period), ordinary income of ¥436 million (14.5% of the prior-year period), and profit attributable to owners of the parent of ¥438 million (17.8% of the prior-year period).」
The consolidated results for the cumulative second-quarter period of FY2021 have been updated. Revenue declined, and operating income turned from a profit in the prior-year period to an operating loss. - FY2021-Q1First-quarter results updated; swung into the redAnnual report
「For the consolidated cumulative period, revenue was ¥135,075 million, operating loss was ¥932 million, compared with operating profit of ¥551 million in the year-earlier period, ordinary loss was ¥225 million, compared with ordinary profit of ¥1,356 million, and loss attributable to owners of the parent was ¥257 million, compared with profit attributable to owners of the parent of ¥1,053 million.」
The consolidated results for the first quarter of FY2021 have been updated. Revenue declined year on year, and operating profit, ordinary profit and profit attributable to owners of the parent all turned into losses. - FY2020Full-year results updated; operating profit up, ordinary profit and net profit downAnnual report
「For the current consolidated fiscal year, revenue was ¥562,505 million, up 0.5% from the previous consolidated fiscal year. Operating profit was ¥3,556 million, up 26.0%, ordinary profit was ¥6,404 million, down 7.3%, and profit attributable to owners of the parent was ¥4,642 million, down 8.7%.」
The consolidated results for FY2020 have been updated. Revenue and operating profit increased, while ordinary profit and profit attributable to owners of the parent declined mainly because amortisation of negative goodwill had ended. - FY2020-Q3Quarterly results updated; revenue and profit up (revenue, operating profit and net profit up, ordinary profit down)Annual report
「For the consolidated cumulative period, revenue was ¥432,774 million, operating profit was ¥3,090 million, ordinary profit was ¥5,404 million, down to 97.3% year on year mainly because amortisation of negative goodwill recognised through the previous fiscal year had ended, and profit attributable to owners of the parent was ¥4,633 million, up to 106.9% year on year due to gains on the sale of investment securities and other factors.」
The consolidated results for the cumulative period of the third quarter of FY2020 have been updated. Revenue, operating profit and profit attributable to owners of the parent exceeded the year-earlier period, while ordinary profit was below it. - FY2020-Q2First-half results updated; revenue up, profit down (operating profit up, ordinary profit and net profit down)Annual report
「For the consolidated cumulative period, revenue was ¥285,519 million, operating profit was ¥1,436 million, ordinary profit was ¥3,018 million, down to 96.4% year on year mainly because amortisation of negative goodwill recognised through the previous fiscal year had ended, and profit attributable to owners of the parent was ¥2,464 million, down to 92.8% year on year. Results were affected by rush demand ahead of the consumption tax increase in October 2019, among other factors.」
The consolidated results for the cumulative period of the second quarter of FY2020 have been updated. Revenue and operating profit exceeded the year-earlier period, while ordinary profit and profit attributable to owners of the parent were below it. - FY2020-Q1Quarterly results updated; revenue up, operating and ordinary profit down, net profit upAnnual report
「For the consolidated cumulative period, revenue was ¥142,689 million, operating profit was ¥551 million, ordinary profit was ¥1,356 million, down to 91.1% year on year mainly because amortisation of negative goodwill recognised through the previous fiscal year had ended, and profit attributable to owners of the parent was ¥1,053 million, up to 102.5% year on year due to a gain on the sale of part of the cross-shareholdings.」
The consolidated results for the first quarter of FY2020 have been updated. Revenue increased, operating profit and ordinary profit declined, and profit attributable to owners of the parent increased. - FY2019Full-year results updated; revenue down, profit upAnnual report
「For the current consolidated fiscal year, revenue was ¥559,712 million, operating profit was ¥2,821 million, ordinary profit was ¥6,909 million and profit attributable to owners of the parent was ¥5,084 million. The year-on-year changes were 99.0%, 118.3%, 110.1% and 113.8%, respectively.」
The consolidated results for FY2019 have been updated. Revenue declined, while operating profit, ordinary profit and profit attributable to owners of the parent increased. - FY2019-Q3Quarterly results updated; revenue down, profit upAnnual report
「For the consolidated cumulative period, revenue was ¥425,595 million, operating profit was ¥2,387 million, ordinary profit was ¥5,552 million and profit attributable to owners of the parent was ¥4,333 million. The year-on-year changes were 98.2%, 142.8%, 125.1% and 133.6%, respectively.」
The consolidated results for the cumulative period of the third quarter of FY2019 have been updated. Revenue declined year on year, while operating profit, ordinary profit and profit attributable to owners of the parent exceeded the year-earlier period. - FY2019-Q2First-half results updated; revenue down, profit upAnnual report
「For the consolidated cumulative period of the current second quarter, revenue was ¥274,976 million, operating profit was ¥922 million, ordinary profit was ¥3,132 million and profit attributable to owners of the parent was ¥2,654 million. The year-on-year changes were 98.1%, 219.2%, 137.9% and 156.4%, respectively.」
The consolidated results for the cumulative period of the second quarter of FY2019 have been updated. Revenue declined year on year, while operating profit, ordinary profit and profit attributable to owners of the parent increased. - FY2019-Q1Quarterly results updated; profit upAnnual report
「For the consolidated cumulative period, revenue was ¥141,604 million, operating profit was ¥563 million, ordinary profit was ¥1,488 million and profit attributable to owners of the parent was ¥1,027 million. The year-on-year changes were 99.0%, 115.7%, 106.8% and 108.3%, respectively.」
The consolidated results for the first quarter of FY2019 have been updated. Revenue declined year on year, while operating profit, ordinary profit and profit attributable to owners of the parent exceeded the year-earlier period. - FY2018Full-year results updated; revenue and profit downAnnual report
「During the consolidated fiscal year, the impact of lower sales of hepatitis C drugs and the emergency price revision for the anticancer drug Opdivo, among other factors, was substantial in the Group's principal business, pharmaceutical wholesaling. Results were revenue of ¥565,589 million, 97.3% of the year-earlier period; operating income of ¥2,384 million, 74.3%; ordinary income of ¥6,276 million, 89.8%; and net income attributable to owners of the parent of ¥4,467 million, 93.5%.」
The consolidated results for FY2018 have been updated. Revenue, operating profit, ordinary profit and profit attributable to owners of the parent were all below the year-earlier period. - FY2018-Q3Quarterly results updated; revenue and profit downAnnual report
「During the first nine months, the impact of lower sales of hepatitis C drugs and the emergency price revision for the anticancer drug Opdivo, among other factors, was substantial in the Group's principal business, pharmaceutical wholesaling. Results were revenue of ¥433,608 million, 97.3% of the year-earlier period; operating income of ¥1,672 million, 60.6%; ordinary income of ¥4,438 million, 79.8%; and quarterly net income attributable to owners of the parent of ¥3,243 million, 85.4%.」
The consolidated results for the cumulative period of the third quarter of FY2018 have been updated. Revenue, operating profit, ordinary profit and profit attributable to owners of the parent were all below the year-earlier period. - FY2018-Q2First-half results updated; revenue and profit downAnnual report
「The results were revenue of ¥280,206 million, operating profit of ¥421 million, ordinary profit of ¥2,271 million and profit attributable to owners of the parent of ¥1,697 million. The year-on-year changes were 95.6%, 26.9%, 65.8% and 72.3%, respectively.」
The consolidated results for the cumulative period of the second quarter of FY2018 have been updated. Revenue and profit declined year on year, against a backdrop of a contraction in the prescription pharmaceutical market. - FY2018-Q1Quarterly actual results updateAnnual report
「The results were revenue of ¥143,052 million, operating profit of ¥487 million, ordinary profit of ¥1,393 million and profit attributable to owners of the parent of ¥948 million. The year-on-year changes were 94.1%, 34.3%, 58.9% and 58.4%, respectively.」
The consolidated results for the first quarter of FY2018 have been added. Revenue and profit declined year on year. - FY2017Full-year results updated; lower profitAnnual report
「For the current consolidated fiscal year, revenue was ¥581,079 million, operating profit was ¥3,207 million, ordinary profit was ¥6,987 million and profit attributable to owners of the parent was ¥4,778 million. The year-on-year changes were 93.6%, 46.5%, 66.0% and 72.9%, respectively.」
The consolidated full-year results for FY2017 have been updated. Revenue and profit declined, following the strong performance of new drugs in the previous fiscal year, mainly because of the contraction of the hepatitis C treatment market. - FY2017-Q2Update to half-year resultsAnnual report
「For the consolidated cumulative period of the current second quarter, revenue was ¥293,202 million, operating profit was ¥1,566 million, ordinary profit was ¥3,453 million and profit attributable to owners of the parent was ¥2,347 million. The year-on-year changes were 102.2%, 157.9%, 121.0% and 121.3%, respectively.」
The consolidated results for the cumulative period of the second quarter of FY2017 have been added. - FY2017-Q1Quarterly actual results updateAnnual report
「Under these circumstances, the Company focused on sales of products covered by the premium system for promoting the creation of new drugs and the elimination of off-label drugs, as well as new products (branded products), particularly new drugs such as hepatitis C treatments, which recorded explosive sales in the previous fiscal year. For the consolidated cumulative period, revenue was ¥152,081 million, operating profit was ¥1,418 million, ordinary profit was ¥2,366 million and profit attributable to owners of the parent was ¥1,624 million. The year-on-year changes were 106.9%, 417.3%, 182.0% and 175.0%, respectively.」
The disclosure adds the focus on new-drug sales and the revenue and profit results for the first quarter of FY2017. - FY2016First statedAnnual report
「As new drugs, including treatments for hepatitis C, performed significantly better than expected, revenue was ¥621,040 million, operating profit was ¥6,892 million, ordinary profit was ¥10,584 million and profit attributable to owners of the parent was ¥6,556 million. The year-on-year changes were 113.3%, 380.2%, 172.8% and 144.8%, respectively.」
The FY2016 results reported increases in revenue and profit driven by new-drug sales.